24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

This study is testing an alternating chemotherapy regimen — switching between two drug combinations (gemcitabine/nab-paclitaxel and mFOLFIRINOX) — in patients with borderline resectable pancreatic cancer (cancer that is on the border of being surgically removable). The goal is to shrink the tumor enough to allow surgery while reducing the side effects of any single chemotherapy approach. **You may be eligible if...** - You are 18 or older - You have been diagnosed with borderline resectable pancreatic cancer (confirmed by a multidisciplinary tumor board) - You have had a CT scan of the chest, abdomen, and pelvis within the past 45 days - You are in good physical condition (ECOG 0–1) - If female of childbearing potential, you have a negative pregnancy test within 14 days of enrollment **You may NOT be eligible if...** - Your cancer is clearly resectable (already operable) or clearly unresectable - You have already started chemotherapy for this cancer - Your organ function does not meet the required levels - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.